Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs Novavax Inc (NVAX) Price & Performance

Cytokinetics IncTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs Novavax Inc — how do they compare? Cytokinetics Inc trades at $76.78 (market cap $10.63B), while Novavax Inc trades at $7.97 (market cap $1.31B). The key difference: Cytokinetics Inc is far larger — about 8.1× Novavax Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

CYTKNVAX
Market Cap
$10.63B$1.31B
Sector
TechnologyHealth
52-Week High
$87.26$11.19
52-Week Low
$34.31$6.22
Enterprise Value
$10.74B$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.

The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.

Novavax Inc

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX